Tags

Type your tag names separated by a space and hit enter

Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial.
Nutr Res 2013; 33(12):1026-33NR

Abstract

Soy foods contain several components, notably, isoflavones and amino acids, that may improve cardiovascular health. We evaluated the long-term effect of soy protein and/or soy isoflavones supplementation on serum lipids and inflammatory markers using a 1-year randomized, double-blind, placebo-control, clinical trial in 131 healthy ambulatory women older than 60 years. We hypothesized that soy protein, in combination with isoflavones, would have the largest positive effect on coronary heart disease risk factors (serum lipids and inflammatory markers) compared with either intervention alone and that, within groups receiving isoflavones, equol producers would have more positive effects on coronary heart disease risk factors than nonequol producers. After a 1-month baseline period, participants were randomized into 1 of 4 intervention groups: soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents), soy protein and placebo tablets, control protein and isoflavone tablets, or control protein and placebo tablets. T Tests were used to assess differences between equol and nonequol producers. Ninety-seven women completed the trial. Consumption of protein powder and isoflavone tablets did not differ among groups, and compliance with study powder and tablets was 79% and 90%, respectively. After 1 year, in the entire population, there were either no or little effects on serum lipids and inflammatory markers, regardless of treatment group. Equol producers, when analyzed separately, had significant improvements in total cholesterol/high-density lipoprotein and low-density lipoprotein/high-density lipoprotein ratios (-5.9%, P = .02; -7.2%, P = .04 respectively). Soy protein and isoflavone (either alone or together) did not impact serum lipids or inflammatory markers. Therefore, they should not be considered an effective intervention to prevent cardiovascular disease because of lipid modification in healthy late postmenopausal women lacking the ability to produce equol.

Authors+Show Affiliations

Department of Nutritional Sciences, University of Connecticut, Storrs, CT; Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

24267042

Citation

Mangano, Kelsey M., et al. "Soy Proteins and Isoflavones Reduce Interleukin-6 but Not Serum Lipids in Older Women: a Randomized Controlled Trial." Nutrition Research (New York, N.Y.), vol. 33, no. 12, 2013, pp. 1026-33.
Mangano KM, Hutchins-Wiese HL, Kenny AM, et al. Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial. Nutr Res. 2013;33(12):1026-33.
Mangano, K. M., Hutchins-Wiese, H. L., Kenny, A. M., Walsh, S. J., Abourizk, R. H., Bruno, R. S., ... Kerstetter, J. E. (2013). Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial. Nutrition Research (New York, N.Y.), 33(12), pp. 1026-33. doi:10.1016/j.nutres.2013.08.009.
Mangano KM, et al. Soy Proteins and Isoflavones Reduce Interleukin-6 but Not Serum Lipids in Older Women: a Randomized Controlled Trial. Nutr Res. 2013;33(12):1026-33. PubMed PMID: 24267042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial. AU - Mangano,Kelsey M, AU - Hutchins-Wiese,Heather L, AU - Kenny,Anne M, AU - Walsh,Stephen J, AU - Abourizk,Robin H, AU - Bruno,Richard S, AU - Lipcius,Rosanne, AU - Fall,Pamela, AU - Kleppinger,Alison, AU - Kenyon-Pesce,Lisa, AU - Prestwood,Karen M, AU - Kerstetter,Jane E, Y1 - 2013/09/18/ PY - 2013/04/08/received PY - 2013/08/02/revised PY - 2013/08/13/accepted PY - 2013/11/26/entrez PY - 2013/11/26/pubmed PY - 2014/7/8/medline KW - ANOVA KW - BMI KW - CHD KW - CVD KW - Cardiovascular health KW - Equol producer KW - HDL KW - IL-6 KW - LDL KW - Postmenopausal women KW - Serum lipids KW - Soy isoflavones KW - Soy protein KW - TC KW - TG KW - analysis of variance KW - body mass index KW - cardiovascular disease KW - coronary heart disease KW - high-density lipoprotein KW - high-sensitivity C-reactive protein KW - hsCRP KW - interleukin-6 KW - low-density lipoprotein KW - total cholesterol KW - triglycerides SP - 1026 EP - 33 JF - Nutrition research (New York, N.Y.) JO - Nutr Res VL - 33 IS - 12 N2 - Soy foods contain several components, notably, isoflavones and amino acids, that may improve cardiovascular health. We evaluated the long-term effect of soy protein and/or soy isoflavones supplementation on serum lipids and inflammatory markers using a 1-year randomized, double-blind, placebo-control, clinical trial in 131 healthy ambulatory women older than 60 years. We hypothesized that soy protein, in combination with isoflavones, would have the largest positive effect on coronary heart disease risk factors (serum lipids and inflammatory markers) compared with either intervention alone and that, within groups receiving isoflavones, equol producers would have more positive effects on coronary heart disease risk factors than nonequol producers. After a 1-month baseline period, participants were randomized into 1 of 4 intervention groups: soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents), soy protein and placebo tablets, control protein and isoflavone tablets, or control protein and placebo tablets. T Tests were used to assess differences between equol and nonequol producers. Ninety-seven women completed the trial. Consumption of protein powder and isoflavone tablets did not differ among groups, and compliance with study powder and tablets was 79% and 90%, respectively. After 1 year, in the entire population, there were either no or little effects on serum lipids and inflammatory markers, regardless of treatment group. Equol producers, when analyzed separately, had significant improvements in total cholesterol/high-density lipoprotein and low-density lipoprotein/high-density lipoprotein ratios (-5.9%, P = .02; -7.2%, P = .04 respectively). Soy protein and isoflavone (either alone or together) did not impact serum lipids or inflammatory markers. Therefore, they should not be considered an effective intervention to prevent cardiovascular disease because of lipid modification in healthy late postmenopausal women lacking the ability to produce equol. SN - 1879-0739 UR - https://www.unboundmedicine.com/medline/citation/24267042/Soy_proteins_and_isoflavones_reduce_interleukin_6_but_not_serum_lipids_in_older_women:_a_randomized_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0271-5317(13)00195-4 DB - PRIME DP - Unbound Medicine ER -